Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Feb;67(2):232–236. doi: 10.1038/bjc.1993.45

Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro.

J A Foekens 1, A M Sieuwerts 1, E M Stuurman-Smeets 1, H A Peters 1, J G Klijn 1
PMCID: PMC1968164  PMID: 8431356

Abstract

The polyanionic compound suramin can inhibit the proliferation of cells of various origin, including from breast cancer. We have studied the effects of suramin on cell cycle kinetics and distribution of MCF-7 human breast cancer cells in vitro. It was found that both under serum-containing and serum-free culture conditions, and in the absence or presence of oestradiol or insulin-like growth factor-1, prolonged exposure (> or = 48 h) to suramin caused an accumulation of surviving cells in the G2/M-phase of the cell cycle. At a concentration of more than 100 micrograms ml-1 suramin significantly inhibited cell proliferation. The observed effects of suramin on breast cancer cells in vitro, i.e. antiproliferative effects and accumulation of cells in the G2/M-phase of the cell cycle, may have beneficial consequences in the application of treatment strategies based on a combination of suramin with cell cycle specific drugs or radiation therapy.

Full text

PDF
232

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berns E. M., Schuurmans A. L., Bolt J., Lamb D. J., Foekens J. A., Mulder E. Antiproliferative effects of suramin on androgen responsive tumour cells. Eur J Cancer. 1990 Apr;26(4):470–474. doi: 10.1016/0277-5379(90)90018-o. [DOI] [PubMed] [Google Scholar]
  2. Betsholtz C., Westermark B., Ek B., Heldin C. H. Coexpression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: implications for autocrine receptor activation. Cell. 1984 Dec;39(3 Pt 2):447–457. doi: 10.1016/0092-8674(84)90452-5. [DOI] [PubMed] [Google Scholar]
  3. Bontenbal M., Sieuwerts A. M., Klijn J. G., Peters H. A., Krijnen H. L., Sonneveld P., Foekens J. A. Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells. Br J Cancer. 1989 Nov;60(5):688–692. doi: 10.1038/bjc.1989.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987 Feb 15;47(4):936–942. [PubMed] [Google Scholar]
  5. Coffey R. J., Jr, Leof E. B., Shipley G. D., Moses H. L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol. 1987 Jul;132(1):143–148. doi: 10.1002/jcp.1041320120. [DOI] [PubMed] [Google Scholar]
  6. Coughlin S. R., Barr P. J., Cousens L. S., Fretto L. J., Williams L. T. Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo. J Biol Chem. 1988 Jan 15;263(2):988–993. [PubMed] [Google Scholar]
  7. Eisenberger M. A., Fontana J. A. Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer. J Natl Cancer Inst. 1992 Jan 1;84(1):3–5. doi: 10.1093/jnci/84.1.3. [DOI] [PubMed] [Google Scholar]
  8. Foekens J. A., Sieuwerts A. M., Stuurman-Smeets E. M., Dorssers L. C., Berns E. M., Klijn J. G. Pleiotropic actions of suramin on the proliferation of human breast-cancer cells in vitro. Int J Cancer. 1992 May 28;51(3):439–444. doi: 10.1002/ijc.2910510317. [DOI] [PubMed] [Google Scholar]
  9. Fruehauf J. P., Myers C. E., Sinha B. K. Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst. 1990 Jul 18;82(14):1206–1209. doi: 10.1093/jnci/82.14.1206. [DOI] [PubMed] [Google Scholar]
  10. Jindal H. K., Anderson C. W., Davis R. G., Vishwanatha J. K. Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases. Cancer Res. 1990 Dec 15;50(24):7754–7757. [PubMed] [Google Scholar]
  11. Klijn J. G., Setyono-Han B., Bakker G. H., van der Burg M. E., Bontenbal M., Peters H. A., Sieuwerts A. M., Berns P. M., Foekens J. A. Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1089–1095. doi: 10.1016/0960-0760(90)90471-v. [DOI] [PubMed] [Google Scholar]
  12. Kopp R., Pfeiffer A. Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res. 1990 Oct 15;50(20):6490–6496. [PubMed] [Google Scholar]
  13. La Rocca R. V., Danesi R., Cooper M. R., Jamis-Dow C. A., Ewing M. W., Linehan W. M., Myers C. E. Effect of suramin on human prostate cancer cells in vitro. J Urol. 1991 Feb;145(2):393–398. doi: 10.1016/s0022-5347(17)38351-9. [DOI] [PubMed] [Google Scholar]
  14. La Rocca R. V., Stein C. A., Danesi R., Myers C. E. Suramin, a novel antitumor compound. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):893–898. doi: 10.1016/0960-0760(90)90439-r. [DOI] [PubMed] [Google Scholar]
  15. Olivier S., Formento P., Fischel J. L., Etienne M. C., Milano G. Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. Eur J Cancer. 1990;26(8):867–871. doi: 10.1016/0277-5379(90)90186-w. [DOI] [PubMed] [Google Scholar]
  16. Pollak M., Richard M. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst. 1990 Aug 15;82(16):1349–1352. doi: 10.1093/jnci/82.16.1349. [DOI] [PubMed] [Google Scholar]
  17. Spigelman Z., Dowers A., Kennedy S., DiSorbo D., O'Brien M., Barr R., McCaffrey R. Antiproliferative effects of suramin on lymphoid cells. Cancer Res. 1987 Sep 1;47(17):4694–4698. [PubMed] [Google Scholar]
  18. Stein C. A., LaRocca R. V., Thomas R., McAtee N., Myers C. E. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989 Apr;7(4):499–508. doi: 10.1200/JCO.1989.7.4.499. [DOI] [PubMed] [Google Scholar]
  19. Vierhapper H., Nowotny, Mostbeck G., Waldhäusl W. Effect of suramin in a patient with adrenocortical carcinoma. Lancet. 1989 May 27;1(8648):1207–1208. doi: 10.1016/s0140-6736(89)92790-6. [DOI] [PubMed] [Google Scholar]
  20. Vignon F., Prebois C., Rochefort H. Inhibition of breast cancer growth by suramin. J Natl Cancer Inst. 1992 Jan 1;84(1):38–42. doi: 10.1093/jnci/84.1.38. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES